ReviewFrontiers in psychiatry2022
Biology of cyclooxygenase-2: An application in depression therapeutics.
Review in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Blunted Niacin Skin Flushing Response in Mood Disorders: A Meta-Analysis of Case-Control Studies.Depression and anxiety · 2026Pooled it
- Exploring the bidirectional relationship between depressive disorder and dyslipidemia: a systematic review and meta-analysis.Frontiers in psychiatry · 2025Pooled it
- Association between Depression and Risk of Colorectal Cancer and Polyps: A Prospective Cohort Study from the Nurses' Health Study II.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Article
- Schaftoside inhibits neuroinflammation and exerts antidepressant effects through METTL3-mediated m6A modification of circ_0001470 sponging miR-183-5p to regulate MAP3K1 expression.Psychopharmacology · 2026Article
- Therapeutic potential ofIn silico pharmacology · 2026Article
- The role of arachidonic acid metabolites in major depressive disorder: mechanisms and therapeutic implications.Metabolic brain disease · 2025Review
- Article
- Molecular Mechanisms Underlying Apple Extract Ameliorates Depression-Incident Cognitive Dysfunction Based on Network Pharmacology.Food science & nutrition · 2025Article
- Unlocking New Pharma/Nutraceutical Frontiers With Neuroprotective Properties of ThreeFood science & nutrition · 2025Article
- Neuroinflammation-A Crucial Factor in the Pathophysiology of Depression-A Comprehensive Review.Biomolecules · 2025Review
- BDNF/BDNF-AS Gene Polymorphisms Modulate Treatment Response and Remission in Bipolar Disorder: A Randomized Clinical Trial.Journal of personalized medicine · 2025Article
- A Fast-Binding, Functionally Reversible, COX-2 Radiotracer for CNS PET Imaging.ACS central science · 2024Article
- Article
- Role of brain renin-angiotensin system in depression: A new perspective.CNS neuroscience & therapeutics · 2024Review
- Mitochondrial Metabolism in Major Depressive Disorder: From Early Diagnosis to Emerging Treatment Options.Journal of clinical medicine · 2024Review
- Network pharmacology- and molecular docking-based investigation on the mechanism of action of Si-ni San in the treatment of depression combined with anxiety and experimental verification in adolescent rats.Frontiers in psychiatry · 2024Article
- Mutations in ARHGEF15 cause autosomal dominant hereditary cerebral small vessel disease and osteoporotic fracture.Acta neuropathologica · 2023Article
- Flavonols in Action: Targeting Oxidative Stress and Neuroinflammation in Major Depressive Disorder.International journal of molecular sciences · 2023Review
- Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories.Frontiers in psychiatry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depressive Disorder is a common mood disorder or affective disorder that is dominated by depressed mood. It is characterized by a high incidence and recurrence. The onset of depression is related to genetic, biological and psychosocial factors. However, the pathogenesis is still unclear. In recent years, there has been an increasing amount of research on the inflammatory hypothesis of depression, in which cyclo-oxygen-ase 2 (COX-2), a pro-inflammatory cytokine, is closely associated with depression. A variety of chemical drugs and natural products have been found to exert therapeutic effects by modulating COX-2 levels. This paper summarizes the relationship between COX-2 and depression in terms of neuroinflammation, intestinal flora, neurotransmitters, HPA axis, mitochondrial dysfunction and hippocampal neuronal damage, which can provide a reference for further preventive control, clinical treatment and scientific research on depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.